Fight Aging!

That part of the life science research community focused on better understanding and treating the panoply of age-related neurodegenerative conditions is increasingly focused on chronic inflammation in the brain. Aging, and neurodegenerative disease, is characterized by excessive, unresolved inflammatory signaling in brain tissue. A sizable focus is given to increased inflammatory behavior in microglia, for example, and how these innate immune cells of the central nervous system might be adjusted to reduce this problem. But much of the ongoing portfolio of fundamental research seeks to understand how the underlying biochemistry of aging gives rise to a state of chronic inflammatory signaling in various cell populations in the brain, including microglia, but not only microglia.

The authors of today's open access paper review review a topic of increasing interest in this context, the maladative overactivation of cGAS-STING signaling in aged brain cells. This is actually a global phenomenon throughout the body, so much of what is said here applies to other tissues as well. STING is a central hub in the regulation of inflammatory signaling, and is activated by a range of sensor proteins that react to various different circumstances in the cell. cGAS detects double-stranded DNA in the cytosol of the cell, where no double-stranded DNA should exist. This is an evolved defense against invasive pathogens such as bacteria and viruses, but it is is also triggered in a cell that has become dysfunctional enough to allow leakage of DNA fragments from the nucleus or mitochondria.

Aged cells are characterized by excessive cGAS-STING activation in particular due to mitochondrial dysfunction allowing mitochondrial DNA fragments to escape the mitochondria. This is one of the reasons why addressing mitochondrial dysfunction in the aging brain may help with neurodegeneration. It isn't just a matter of a dysfunctional energy metabolism allowing cells to run down, but also a matter of tidying up mitochondrial DNA to reduce cGAS activity.

Expanding roles of cGAS-STING signaling in neuroinflammation

The sensing of nucleic acids is a central component of innate immunity, enabling host defense against infection while shaping inflammatory responses within the central nervous system (CNS). Pattern recognition receptors (PRRs) function as molecular sentries that detect both pathogen-derived nucleic acids and endogenous danger signals. Among these, DNA is an important signal of infection and inflammation. Several PRRs act as DNA sensors, and cyclic GMP-AMP synthase (cGAS) has the unique ability to directly and sequence-independently detect double-stranded DNA (dsDNA) in both the cytosol and nucleus. The dsDNA inside cells sensed by cGAS originates from diverse sources, ranging from foreign viral or bacterial DNA to endogenous self-DNA caused by mitochondrial damage or chromatin instability. Upon binding to dsDNA, cGAS activates the adaptor protein STING and elicits a strong interferon (IFN) response. cGAS is highly evolutionarily conserved from bacteria to mammals, underscoring its fundamental role in innate immunity.

Neuroinflammation is typically characterized by persistent, low-grade inflammatory signaling, underscoring the importance of identifying the precise triggers and sustaining mechanisms of cGAS-STING activation in the CNS. Studies in Alzheimer's disease models have implicated mitochondrial DNA (mtDNA) leakage as a key activator of this pathway. However, whether additional sources of cytosolic DNA, or even non-DNA ligands, contribute to chronic cGAS-STING engagement remains unclear. This issue is particularly relevant in nonimmune cells such as neurons and endothelial cells, where the mechanisms governing cGAS activation, signal amplification, and persistence are still largely undefined.

The growing recognition of cGAS-STING signaling as a driver of chronic neuroinflammation positions this pathway as an attractive, yet complex, therapeutic target for brain disorders. Sustained or inappropriate activation of cGAS-STING in the CNS is increasingly linked to neurodegeneration, cognitive decline, and aging. This highlights the need for therapeutic strategies that selectively attenuate pathological signaling while preserving essential antiviral functions. Pharmacological inhibition of cGAS or STING has shown encouraging results in preclinical models of neurodegenerative disease and brain injury, where suppression of IFN-I and downstream inflammatory cascades reduce neuronal loss and improve functional outcomes. Small-molecule cGAS inhibitors, STING antagonists, and modulators of cyclic dinucleotide metabolism represent the most direct approaches.

While targeting the cGAS-STING pathway is of therapeutic interest, chronic inhibition may carry risks. Given its role in antiviral defense and tumor surveillance, sustained suppression could increase susceptibility to infection or impair immune function. A potential therapeutic strategy is partial and context-dependent modulation, as neurodegenerative conditions are often associated with elevated cGAS-STING activity and IFN-I signaling. To mitigate systemic effects, CNS-selective or temporally restricted approaches may be beneficial. Over time, more refined strategies, including microglia-biased small molecules or glia-targeted degraders, may further improve specificity and safety.